Zacks Research Forecasts Perrigo's Q2 Earnings (NYSE:PRGO)

Key Points

• Zacks Research sharply cut Perrigo’s Q2 2026 EPS estimate to $0.30 from $0.45, while keeping a Hold rating on the stock. The firm also trimmed its FY2026 forecast to $2.10 EPS, roughly in line with the broader consensus of $2.12.
• Perrigo’s latest quarterly results were mixed: EPS of $0.43 beat estimates, but revenue of $841.8 million missed expectations and fell 7.2% year over year. The company also guided FY2026 EPS to a range of $2.25 to $2.55.
• The stock offers a high dividend yield, with a quarterly payout of $0.29 per share translating to an annualized dividend of $1.16 and a yield of about 10.1%. However, the company’s shares remain under pressure, trading well below their 200-day moving average and near the low end of the 1-year range.

Perrigo Company plc (NYSE:PRGO - Free Report) - Investment analysts at Zacks Research lowered their Q2 2026 EPS estimates for shares of Perrigo in a research note issued on Wednesday, May 27th. Zacks Research analyst Team now expects that the company will earn $0.30 per share for the quarter, down from their previous forecast of $0.45. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Perrigo's current full-year earnings is $2.12 per share. Zacks Research also issued estimates for Perrigo's FY2027 earnings at $2.50 EPS, Q1 2028 earnings at $0.70 EPS and FY2028 earnings at $2.72 EPS.

Several other analysts have also recently weighed in on PRGO. Weiss Ratings raised shares of Perrigo from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, May 13th. Jefferies Financial Group restated a "hold" rating on shares of Perrigo in a report on Thursday, February 26th. Finally, Canaccord Genuity Group decreased their price objective on shares of Perrigo from $20.00 to $17.00 and set a "buy" rating on the stock in a report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Perrigo has a consensus rating of "Hold" and an average price target of $19.33.

Perrigo Stock Performance

Perrigo stock opened at $11.45 on Friday. The firm has a 50 day simple moving average of $10.95 and a 200-day simple moving average of $12.65. Perrigo has a 1-year low of $9.23 and a 1-year high of $28.43. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -0.87, a price-to-earnings-growth ratio of 1.32 and a beta of 0.52.

Perrigo (NYSE:PRGO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The business had revenue of $841.80 million during the quarter, compared to analysts' expectations of $1.04 billion. During the same quarter in the prior year, the company posted $0.60 EPS. The business's revenue for the quarter was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Hedge Funds Weigh In On Perrigo

Several large investors have recently made changes to their positions in PRGO. Fuller & Thaler Asset Management Inc. lifted its holdings in Perrigo by 291.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company's stock worth $108,921,000 after buying an additional 5,828,076 shares in the last quarter. Norges Bank acquired a new stake in Perrigo during the 4th quarter worth approximately $42,607,000. Invesco Ltd. lifted its holdings in Perrigo by 134.2% during the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company's stock worth $63,230,000 after buying an additional 2,602,724 shares in the last quarter. ION Fund Management Ltd acquired a new stake in Perrigo during the 4th quarter worth approximately $24,499,000. Finally, Vanguard Group Inc. lifted its holdings in Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company's stock worth $208,568,000 after buying an additional 1,101,154 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 10.1%. The ex-dividend date is Friday, May 29th. Perrigo's dividend payout ratio is currently -8.85%.

Trending Headlines about Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Zacks Research raised Perrigo’s Q3 2026 EPS estimate to $0.64 from $0.55 and lifted Q4 2026 to $0.72 from $0.61, suggesting improving profitability later this year.
• Positive Sentiment: The firm also increased its Q2 2027 estimate to $0.58 from $0.55 and Q4 2027 to $0.72 from $0.66, indicating better longer-term earnings momentum.
• Neutral Sentiment: Zacks maintained a Hold rating on Perrigo, which does not signal a strong bullish or bearish change in opinion.
• Neutral Sentiment: Despite the revisions, Zacks’ estimates remain close to consensus for FY2026, with its new $2.10 EPS view roughly in line with the market’s $2.12 expectation.
• Negative Sentiment: The most concerning update was a sharper cut to Q2 2026 EPS to $0.30 from $0.45, pointing to softer expected near-term earnings.
• Negative Sentiment: Zacks also trimmed its FY2026 estimate to $2.10 from $2.18, plus lowered Q1 2027, Q3 2027 and Q1 2028 forecasts, which may weigh on the shares.
• Negative Sentiment: FY2028 EPS was reduced to $2.72 from $2.88, showing some moderation in the longer-range outlook as well.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo's focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo's operations span research and development, manufacturing, quality assurance and global distribution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.